Vivos Therapeutics, Inc. – NASDAQ:VVOS

Add to watchlist

$4.12

-0.53

-11.4%

Market closed

Open in 1 day

+65.48%

month

+65.48%

quarter

-60.99%

year

Market Cap	22.45M
Enterprise value	6.15M

P/E	-0.31
EV/Sales	0.26
EV/EBITDA	-0.16
Price/Sales	0.30
Price/Book	1.51
PEG ratio	N/A
EPS	-10.32

Revenue	13.36M
EBITDA	-14.58M
Income	-15.64M
Revenue Q/Q	-11.35%
Revenue Y/Y	-17.70%

Profit margin	-153.59%
Oper. margin	-164.01%
Gross margin	63.27%
EBIT margin	-164.01%
EBITDA margin	-109.12%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Profit margin
Jun 2023	3.39M	-5.52M	-162.83%
Sep 2023	3.30M	-2.09M	-63.41%
Dec 2023	3.24M	-4.25M	-131.13%
Mar 2024	3.41M	-3.76M	-110.06%

Vivos Therapeutics Financials Estimate

Q Y

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Analyst Estimates
Mar 2024	3.41M	-3.76M	-110.06%
Sep 2025	5.1M	-1.30M	-25.53%
Oct 2025	4.5M	-1.70M	-37.96%
Dec 2025	4.8M	-1.50M	-31.26%

Analysts Price target
Financials & Ratios estimates

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Debt to assets
Jun 2023	13749000	11.64M	84.68%
Sep 2023	10317000	10.27M	99.55%
Dec 2023	10730000	10.31M	96.17%
Mar 2024	11804000	11.22M	95.07%

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Cash Flow
Jun 2023	-2.85M	-245K	0
Sep 2023	-2.8M	-154K	0
Dec 2023	-2.74M	-165K	3.56M
Mar 2024	-2.51M	-151K	3.63M

Vivos Therapeutics alternative data

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Employee count
Aug 2023	132
Sep 2023	154
Oct 2023	154
Nov 2023	154
Dec 2023	154
Jan 2024	154
Feb 2024	154
Mar 2024	154
Apr 2024	154
May 2024	114
Jun 2024	114
Jul 2024	114

Vivos Therapeutics
Hedge Funds Holdings Q1 2023

18.20% +10.83%

of VVOS is owned by hedge funds

20 -5

hedge funds hold VVOS stock

3.86M +2.29M

shares is hold by hedge funds

VVOS hedge funds holdings changes

Vivos Therapeutics
Insider Trading

Vivos Therapeutics, Inc. (NASDAQ:VVOS): Insider trades (number of shares)
Period	Buy	Sel
Dec 2022	20000	0
Jun 2023	39021	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	20 Jun 2023	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	14,000	$0.53	$7,420
Purchase	16 Jun 2023	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	10,000	$0.54	$5,400
Purchase	16 Jun 2023	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	5,000	$0.53	$2,650
Purchase	15 Jun 2023	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	21	$0.5	$11
Purchase	14 Jun 2023	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	10,000	$0.49	$4,900
Purchase	23 Dec 2022	HUNTSMAN RONALD KIRK officer: Chief Executive Officer officer: Chief Executive Officer	Common Stock	20,000	$0.5	$10,000
Purchase	1 Jun 2022	HUNTSMAN RONALD KIRK director, 10 percent owner, officer: .. director, 10 percent owner, off..	Common Stock	4,000	$1.83	$7,320
Purchase	31 May 2022	HUNTSMAN RONALD KIRK director, 10 percent owner, officer: .. director, 10 percent owner, off..	Common Stock	8,000	$2.03	$16,240
Purchase	21 Sep 2021	HUNTSMAN RONALD KIRK director, officer: Chief Executive Of.. director, officer: Chief Execut..	Common Stock	5,000	$4.31	$21,550
Purchase	17 Aug 2021	HUNTSMAN RONALD KIRK	Common Stock	5,000	$3	$15,000

VVOS insider trading transactions

Vivos Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 17 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 17 Nov 2023	Q3 2023 Earnings Call Transcript
Q1 2023 9 Jun 2023	Q1 2023 Earnings Call Transcript

VVOS earnings call transcripts

Vivos Therapeutics
Executives

Insider	Age	Compensation
Mr. R. Kirk Huntsman (1958) Co-Founder, Chairman & Chief Executive Officer	67	$455,340
Dr. Gurdev Dave Singh D.M.D., Ph.D. (1958) Founder & Chief Medical Officer (Leave of Absence)	67	$298,510
Mr. Bradford K. Amman (1962) Chief Financial Officer, Treasurer & Sec.	63	$268,940

Vivos Therapeutics
Latest News

Monday, 23 December 2024
09:25	Vivos Therapeutics announces funding boost	proactiveinvestors.com
08:00	Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	globenewswire.com
Wednesday, 18 December 2024
13:01	All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy	zacks.com
Thursday, 14 November 2024
23:31	Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:52	Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3	proactiveinvestors.com
Wednesday, 13 November 2024
17:00	Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call	globenewswire.com
Tuesday, 8 October 2024
09:31	Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment	proactiveinvestors.com
07:30	Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association	globenewswire.com
Thursday, 19 September 2024
08:36	Vivos Therapeutics raises $4.3 from institutional investors	proactiveinvestors.com
Wednesday, 18 September 2024
09:19	Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment	proactiveinvestors.com
07:00	Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring	globenewswire.com
Thursday, 22 August 2024
11:41	3 Trending Biotech Penny Stocks	247wallst.com
Thursday, 15 August 2024
14:05	Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 14 August 2024
16:29	Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships	proactiveinvestors.com
16:05	Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update	globenewswire.com
07:30	Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call	globenewswire.com
Thursday, 27 June 2024
08:45	Vivos Therapeutics reports positive results from pilot of provider-based model	proactiveinvestors.com
07:30	Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model	globenewswire.com
Wednesday, 12 June 2024
09:03	Vivos Therapeutics announces strategic alliance and $7.5M investment	proactiveinvestors.com
07:30	Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance	globenewswire.com
Friday, 17 May 2024
21:02	Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 14 May 2024
16:41	Vivos Therapeutics reports first quarter cost savings, launches revenue-generating initiative	Proactive Investors
Thursday, 11 April 2024
15:32	Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval	Proactive Investors
Tuesday, 9 April 2024
09:31	Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement	Proactive Investors
Monday, 1 April 2024
09:07	Vivos Therapeutics highlights path to cash flow positivity after FDA clearance	Proactive Investors
Thursday, 28 March 2024
23:10	Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript	Seeking Alpha
07:30	Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call	GlobeNewsWire
Thursday, 15 February 2024
09:13	Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant	Proactive Investors
Thursday, 8 February 2024
16:35	Vivos Therapeutics sees opportunities for its FDA-approved oral sleep apnea treatment amid CPAP market disruptions	Proactive Investors
Monday, 8 January 2024
08:18	Vivos Therapeutics reports surge in interest following FDA clearance for oral device treatment of sleep apnea	Proactive Investors

Ideas & Opinions

Seeking Alpha 6 Mar 2022

Vivos Therapeutics: First Take After The Broad Market Sell-Off
Seeking Alpha 30 Jul 2021

Vivos Therapeutics: Reimagining Sleep

Frequently Asked Questions (FAQ)

What's the price of Vivos Therapeutics stock today?

One share of Vivos Therapeutics stock can currently be purchased for approximately $4.12.
When is Vivos Therapeutics's next earnings date?

Unfortunately, Vivos Therapeutics's (VVOS) next earnings date is currently unknown.
Does Vivos Therapeutics pay dividends?

No, Vivos Therapeutics does not pay dividends.
How much money does Vivos Therapeutics make?

Vivos Therapeutics has a market capitalization of 22.45M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 13.87% to 13.8M US dollars.
What is Vivos Therapeutics's stock symbol?

Vivos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VVOS".
What is Vivos Therapeutics's primary industry?

Company operates in the Healthcare sector and Medical - Devices industry.
How do i buy shares of Vivos Therapeutics?

Shares of Vivos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Vivos Therapeutics's key executives?
Vivos Therapeutics's management team includes the following people:
- Mr. R. Kirk Huntsman Co-Founder, Chairman & Chief Executive Officer(age: 67, pay: $455,340)
- Dr. Gurdev Dave Singh D.M.D., Ph.D. Founder & Chief Medical Officer (Leave of Absence)(age: 67, pay: $298,510)
- Mr. Bradford K. Amman Chief Financial Officer, Treasurer & Sec.(age: 63, pay: $268,940)
Is Vivos Therapeutics founder-led company?

Yes, Vivos Therapeutics is a company led by its founders Mr. R. Kirk Huntsman and Dr. Gurdev Dave Singh D.M.D., Ph.D..
How many employees does Vivos Therapeutics have?

As Jul 2024, Vivos Therapeutics employs 114 workers, which is 26% less then previous quarter.
When Vivos Therapeutics went public?

Vivos Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 11 Dec 2020.
What is Vivos Therapeutics's official website?

The official website for Vivos Therapeutics is vivos.com.
Where are Vivos Therapeutics's headquarters?

Vivos Therapeutics is headquartered at 9137 Ridgeline Boulevard, Highlands Ranch, CO.
How can i contact Vivos Therapeutics?

Vivos Therapeutics's mailing address is 9137 Ridgeline Boulevard, Highlands Ranch, CO and company can be reached via phone at +86 69084867.

Vivos Therapeutics, Inc.

vivos.com

Exchange:

NASDAQ

Full time employees:

114

Industry:

Medical - Devices

Sector:

Healthcare

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

+86 69084867

9137 Ridgeline Boulevard
Highlands Ranch, CO 80129

CIK: 0001716166
ISIN: US92859E2072
CUSIP: 92859E108